핵산 샘플 전처리 소모품 시장 - 세계 및 지역별 분석 : 워크플로우, 시료원 유형, 기술, 다운스트림 용도, 최종사용자, 국가별 - 분석과 예측(2026-2036년)

This report can be delivered within 1 working day.

Introduction to the Nucleic Acid Sample Preparation Consumables Market

The global nucleic acid sample preparation consumables market, valued at $1,812.0 million in 2025, is projected to reach $3,207.4 million by 2036, registering a compound annual growth rate (CAGR) of 5.21% from 2026 to 2036 under the realistic scenario.

The global nucleic acid sample preparation consumables market is expanding steadily, driven by the increasing use of molecular diagnostics, the growing number of genetic tests, liquid biopsy applications, cancer and infectious disease testing, and microbial sequencing. Nucleic acid sample preparation consumables are single-use reagents, kits, and materials used to isolate, extract, purify, clean up, concentrate, quantify, and prepare DNA or RNA from biological samples. Consistent sample quality is essential for downstream polymerase chain reaction (PCR), quantitative PCR (qPCR), next-generation sequencing (NGS), microarrays, cloning, and molecular diagnostic workflows. Growing sample volumes, the shift toward repeat molecular testing, diversified specimen types, and increasing use of automation-compatible consumables are supporting recurring market demand.

Market Introduction

The global nucleic acid sample preparation consumables market covers single-use reagents, materials, and specialized kits used in nucleic acid isolation, extraction, purification, clean-up, concentration, quantification, and preparation for downstream molecular applications. Products include magnetic bead-based and silica-based extraction kits, nucleic acid purification and clean-up reagents, binding buffers, wash solutions, elution reagents, and quantification assays. The scope includes consumables used for DNA and RNA originating from blood, plasma, tissue, cells, saliva, swabs, microbial samples, and other biological sources. Sample preparation services and products unrelated to these upstream workflows have been excluded.

The market has developed alongside the expansion of molecular biology, clinical genomics, and laboratory testing. Demand has shifted from conventional manual extraction procedures to standardized, ready-to-use consumables suited to high-throughput and automated laboratory environments. Silica-based extraction remains widely established, while magnetic particle technology is increasingly adopted for efficient separation, high binding efficiency, reproducible yields, and compatibility with robotic platforms. New assays also require better recovery from fragmented cell-free nucleic acids, preserved tissues, low-input clinical specimens, and samples containing inhibitors.

Sample preparation workflows begin with sample collection and appropriate lysis, followed by nucleic acid isolation, extraction, purification, and, when required, clean-up, concentration, or quantification. Different matrices and downstream technologies impose distinct requirements for yield, purity, integrity, and inhibitor removal. DNA-based workflows include genomic DNA, cell-free DNA, microbial DNA, plasmid DNA, and viral DNA. RNA-based workflows include genomic RNA, microbial RNA, viral RNA, and cell-free RNA. The growing use of longitudinal cancer monitoring, infectious disease testing, NGS, and automated laboratory processing is increasing demand for application-specific formats and consistent sample-preparation performance.

Companies operating in the market compete on extraction efficiency, reproducibility, hands-on time, workflow automation, compatibility with varied sample sources, per-preparation cost, and regulatory compliance for relevant clinical applications. As academic and research laboratories, pharmaceutical and biotechnology companies, contract research organizations, applied testing laboratories, and clinical diagnostic centers increase molecular testing activity, vendors with broad DNA and RNA portfolios, reliable supply, and automation-ready consumables are positioned to strengthen their market presence.

Industrial Impact

The global nucleic acid sample preparation consumables market provides a fundamental upstream input for molecular research, diagnostics, and applied testing. Leading participants, including Thermo Fisher Scientific Inc., QIAGEN N.V., Danaher Corporation, F. Hoffmann-La Roche AG, Merck KGaA, Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Omega Bio-tek, Inc., Bio-Rad Laboratories, Inc., and specialized suppliers, develop nucleic acid extraction, purification, clean-up, and quantification consumables. Their offerings support reliable processing of DNA and RNA from increasingly diverse sample types and enable laboratories to scale molecular workflows.

These consumables serve oncology and liquid biopsy testing, infectious disease detection, genetic testing, microbial sequencing, biobanking, pharmaceutical research, forensic analysis, and environmental or food-related testing. High-quality extracted DNA and RNA are essential for accurate PCR and qPCR amplification, NGS library input, and other molecular assays. Demand is recurring because new biological samples typically require fresh extraction and purification reagents, and repeat testing increases consumption per patient or project. Expanding cell-free RNA and high-molecular-weight DNA applications are also creating requirements for specialized kits with improved analyte recovery.

The market influences academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, clinical diagnostic centers, and applied testing laboratories. Automation-compatible magnetic bead formats can reduce manual processing time and improve consistency across large sample batches. However, high consumable costs, specimen complexity, genomic-data privacy considerations, and regulatory or quality requirements for clinical-use products remain obstacles. Suppliers that improve standardization, reproducibility, affordability, and throughput can strengthen adoption across both mature and emerging markets.

Market Segmentation:

Segmentation 1: By Workflow

• Sample Isolation/Extraction/Purification
• DNA/RNA Clean-Up and Concentration
• DNA/RNA Quantification

Sample Isolation/Extraction/Purification Segment to Dominate the Market (by Workflow)

In 2025, sample isolation/extraction/purification accounted for 83.02% of the global nucleic acid sample preparation consumables market. This segment dominates because the initial recovery of DNA or RNA is a necessary step for most molecular assays and requires multiple reagents and disposable components per sample. Rising testing volumes, adoption of liquid biopsy, and the use of automated extraction platforms are expected to sustain demand for lysis, binding, washing, and elution consumables throughout the forecast period.

Segmentation 2: By Source Type

• DNA
  • Cell-Free DNA
  • Genomic DNA
  • Microbial DNA
  • Plasmid DNA
  • Viral DNA
• RNA
  • Genomic RNA
  • Microbial RNA
  • Viral RNA
  • Cell-Free RNA

DNA Segment to Dominate the Market (by Source Type)

In 2025, DNA accounted for 64.09% of the global nucleic acid sample preparation consumables market. The DNA segment leads because of the widespread use of DNA across genetic testing, clinical diagnostics, cancer research, microbial genomics, PCR, NGS, cloning, and other established molecular techniques. Diverse biological samples and the availability of application-specific genomic, cell-free, microbial, plasmid, and viral DNA kits reinforce demand. RNA workflows, including emerging cell-free RNA analysis, are also expanding as laboratories increasingly assess gene expression and other transcriptional information.

Segmentation 3: By Technology

• Silica-Based Technology
• Magnetic Particle Technology
• Other Technologies

Magnetic Particle Technology Segment to Dominate the Market (by Technology)

In 2025, magnetic particle technology held the largest share of the global nucleic acid sample preparation consumables market at 48.39%. Magnetic bead-based extraction enables efficient nucleic acid binding, consistent recovery, reproducible sample processing, and integration with automated high-throughput systems. Lower hands-on time, scalability across specimen types, and suitability for clinical diagnostics and large-volume research workflows support its market position compared with silica-based and alternative technologies.

Segmentation 4: By Downstream Application

• PCR
• qPCR
• NGS
• Cloning
• Microarray
• Blotting Techniques
• Other Applications

qPCR Segment to Dominate the Market (by Downstream Application)

In 2025, qPCR accounted for the largest share, 32.11%, of the global nucleic acid sample preparation consumables market by downstream application. qPCR is widely used in infectious disease diagnostics, gene expression analysis, and routine molecular testing, supporting repeat demand for reliable DNA and RNA extraction, purification, and clean-up kits. Established laboratory infrastructure, relatively rapid assay turnaround, and frequent testing volumes contribute to the segment's leadership. NGS and other applications also support growing requirements for highly pure, consistent nucleic acid inputs.

Segmentation 5: By End User

• Academic Research Institutes and Laboratories
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Applied Testing
• Clinical Diagnostic Centers

Academic Research Institutes and Laboratories to Dominate the Market (by End User)

In 2025, academic research institutes and laboratories led the global nucleic acid sample preparation consumables market with a 44.71% share. Their leadership reflects sustained molecular biology and genomic research, the need for high-quality DNA and RNA preparation, and funding for PCR, NGS, and other downstream applications. Pharmaceutical and biotechnology companies, clinical diagnostic centers, contract research organizations, and applied testing laboratories also generate recurring demand for specialized extraction and purification kits.

Segmentation 6: By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Rest-of-Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Singapore
  • Malaysia
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Philippines
  • Rest-of-Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Rest-of-Latin America
• Middle East and Africa
  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Rest-of-Middle East and Africa

North America to Dominate the Nucleic Acid Sample Preparation Consumables Market (by Region)

In 2025, North America accounted for the largest share of the global nucleic acid sample preparation consumables market at 46.75%. The region's leadership has been supported by the presence of major life sciences suppliers, advanced molecular diagnostic and research infrastructure, and substantial adoption of nucleic acid-based testing in clinical, academic, and pharmaceutical environments. The U.S. leads regional demand owing to its established laboratories, biotechnology sector, precision medicine activity, and continued utilization of genomic and infectious disease testing.

North America is anticipated to retain a leading position through the forecast period. Growth in Asia-Pacific and other emerging markets is supported by investment in molecular testing capacity, expansion of genomic research, increasing adoption of PCR and NGS workflows, and growing availability of automated sample preparation solutions. Regional uptake will continue to depend on laboratory infrastructure, affordability, regulatory requirements, and access to skilled personnel.

Recent Developments in the Nucleic Acid Sample Preparation Consumables Market

• In August 2026, New England Biolabs, Inc. launched the Monarch Mag Cell-free RNA (cfRNA) Extraction Kit, a phenol-free magnetic bead-based solution for recovery of low-abundance circulating RNA from plasma, serum, urine, and cerebrospinal fluid.
• In July 2026, QIAGEN N.V. established a distribution partnership with Hamburg Trading Corporation and opened a QIAGEN Experience Lab in the Philippines to support product demonstrations and laboratory automation training.
• In June 2026, Omega Bio-tek, Inc. launched the Mag-Bind High Molecular Weight DNA Kit (M6311), designed to recover long genomic DNA fragments from blood, buffy coat, saliva, and cultured cells for long-read sequencing applications.
• In October 2025, AutoGen Inc. partnered with Sampled to connect specialized nucleic acid extraction projects with larger-scale extraction and downstream multi-omics services.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Increasing Use of Liquid Biopsy and Cell-Free Nucleic Acid Testing: Growing adoption of cell-free DNA, circulating tumor DNA, and related assays in oncology, treatment monitoring, and non-invasive testing supports recurring demand for upstream sample preparation consumables. Low analyte concentration and high fragmentation make efficient extraction and purification important for dependable downstream molecular analysis. Expanding genetic-testing menus, infectious disease surveillance, microbial sequencing, and clinical NGS testing further increases demand for kits that can process varied specimen types with consistent recovery, purity, and low contamination risk.

Market Challenges

High Cost of Nucleic Acid Sample Preparation Consumables: Extraction and purification kit pricing can increase per-sample laboratory expenditure, especially for specialized specimen types, low-input nucleic acids, and high-throughput testing programs. Laboratories must balance performance requirements with reagent consumption, throughput, and assay costs. Clinical-use products may also face quality-system, validation, documentation, and regional regulatory requirements, extending supplier commercialization timelines. Genetic data protection concerns can indirectly affect molecular testing adoption, although they are not intrinsic limitations of extraction consumables.

Market Opportunities

Shift toward Standardized, Ready-to-Use, and Automation-Compatible Consumables: Laboratories are seeking consumables that simplify validated sample preparation, minimize manual handling, improve lot-to-lot consistency, and integrate with automated or semi-automated extraction systems. Expansion of biobanks, longitudinal molecular testing, and diverse specimen processing creates opportunities for reliable formats suited to blood, plasma, FFPE tissue, saliva, microbial, and other samples. Suppliers able to offer traceable reagents, scalable formats, and specialized cfRNA or high-molecular-weight DNA solutions can address evolving workflow requirements.

How can this report add value to an organization?

Product/Innovation Strategy: The global nucleic acid sample preparation consumables market has been segmented by workflow, source type, technology, downstream application, end user, and region. By assessing demand for isolation, extraction, purification, clean-up, quantification, DNA and RNA sample types, and silica- or magnetic particle-based approaches, the report supports product development and portfolio decisions. It also highlights requirements for qPCR, PCR, NGS, and other molecular applications, along with opportunities in automation and low-input sample processing.

Growth/Marketing Strategy: Rising use of liquid biopsy, recurring molecular diagnostics, genetic testing, infectious disease surveillance, microbial sequencing, and biobanking is supporting market demand. Regional expansion and increased laboratory automation are shaping opportunities for consumable suppliers. Developments in cell-free RNA extraction, high-molecular-weight DNA preparation, application-specific kits, and standardized processing formats are important areas for growth and differentiation.

Competitive Strategy: The nucleic acid sample preparation consumables market includes large integrated life sciences companies and specialist kit manufacturers. Players compete on nucleic acid recovery, sample compatibility, reproducibility, throughput, automation, cost per preparation, and technical support. Competitive positioning is being strengthened through new kit introductions, expanded extraction portfolios, distribution partnerships, application-specific innovations, and integration with automated laboratory platforms.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for global market estimation; 2025 is the base year, and 2026 to 2036 is the forecast period.
• The scope of the report draws on inputs from stakeholders across the nucleic acid sample preparation consumables value chain, including extraction and purification kit suppliers, DNA and RNA consumables manufacturers, magnetic bead and silica technology providers, laboratory automation companies, clinical diagnostic centers, pharmaceutical and biotechnology companies, contract research organizations, applied testing providers, and academic and research institutes.
• Publicly traded companies engaged in nucleic acid sample preparation consumables have been assessed using available financial disclosures and product portfolios. Where direct segment-specific data are unavailable, the research uses relevant company assessments, industry publications, and proxy indicators; the source report identifies these limitations in its market estimation approach.
• The market has been mapped using commercially available single-use consumables and specialized kits for nucleic acid isolation, extraction, purification, clean-up, concentration, quantification, and preparation. Instruments, sample preparation services, and products unrelated to these activities are excluded. Product-level and segment-level revenue allocation is designed to avoid double counting.

Primary Research

The primary research framework encompasses specialists in molecular biology, molecular diagnostics, genomics, and nucleic acid sample preparation across the consumables value chain. Relevant stakeholder categories include extraction and purification kit manufacturers, reagent suppliers, magnetic particle and silica technology providers, molecular diagnostic laboratories, pharmaceutical and biotechnology companies, contract research organizations, applied testing laboratories, and academic research institutes. Industry and technical perspectives inform assessment of market segmentation, workflow requirements, commercial positioning, and qualitative and quantitative market assumptions.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, peer-reviewed articles, white papers, directories, and major databases, among others
• Annual reports, regulatory filings, and investor presentations of the leading market players
• Company websites and a detailed study of their product portfolios
• Publications and information from scientific and regulatory bodies, including WHO, IARC, NIH, NCBI, FDA, and relevant regional regulatory * authorities, together with product documentation and application guidance
• Paid databases, including D&B Hoovers, Bloomberg, Factiva, and Bloomberg Businessweek

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Agilent Technologies, Inc.
• Merck KGaA
• Promega Corporation
• Bio-Rad Laboratories, Inc.
• New England Biolabs
• Omega Bio-tek, Inc.
• Macherey-Nagel GmbH & Co. KG
• Revvity, Inc.
• Zymo Research
• LGC Biosearch Technologies
• AutoGen Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Pricing Analysis
• 1.3 Market Attractiveness: Macro and Micro Factor Analysis
• 1.4 Regulatory Outlook
• 1.5 Key Trends
  • 1.5.1 Transition from Episodic Diagnostic Testing to Longitudinal and Repeat Molecular Testing Workflows
  • 1.5.2 Increasing Fragmentation of Sample Types Driving Demand for Application-Specific Consumables
  • 1.5.3 Expansion from cfDNA to cfRNA and Total Cell-Free Nucleic Acid Extraction
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Increasing Use of Liquid Biopsy and Cell-Free Nucleic Acid Testing
    • 1.6.1.2 Growing Number of Genetic Tests
    • 1.6.1.3 Increasing Prevalence of Infectious Diseases and Cancer Cases
    • 1.6.1.4 Rise in Microbial Sequencing
    • 1.6.1.5 Increasing Adoption of NGS-Based Testing in Clinical Laboratories
  • 1.6.2 Market Restraints
    • 1.6.2.1 Genomic Data Protection
    • 1.6.2.2 High Cost of Nucleic Acid Sample Preparation Consumables
    • 1.6.2.3 Stringent Regulatory and Quality Compliance Requirements
  • 1.6.3 Market Opportunities
    • 1.6.3.1 Development and Increased Utilization of Biobanks in the Healthcare Segment
    • 1.6.3.2 Shift toward Standardized, Ready-to-Use, and Automation-Compatible Sample Preparation Consumables

2 Workflow

• 2.1 Workflow Summary
• 2.2 Growth-Share Matrix
• 2.3 Sample Isolation/Extraction/Purification
• 2.4 DNA/RNA Clean-Up and Concentration
• 2.5 DNA/RNA Quantification

3 Source Type

• 3.1 Source Type Summary
• 3.2 Growth-Share Matrix
• 3.3 DNA
  • 3.3.1 Cell-Free DNA
    • 3.3.1.1 By Sample
    • 3.3.1.2 Blood
    • 3.3.1.3 Serum/Plasma
    • 3.3.1.4 Other Sources
  • 3.3.2 Genomic DNA
    • 3.3.2.1 Blood
    • 3.3.2.2 Body Fluids
    • 3.3.2.3 Buccal
    • 3.3.2.4 Cell/Cultured Cell
    • 3.3.2.5 FFPE
    • 3.3.2.6 Forensic
    • 3.3.2.7 Plant
    • 3.3.2.8 Saliva/Swab
    • 3.3.2.9 Serum/Plasma
    • 3.3.2.10 Tissue
    • 3.3.2.11 Stool, Urine, and Other Samples
  • 3.3.3 Microbial DNA
    • 3.3.3.1 Bacterial
    • 3.3.3.2 Fungus
    • 3.3.3.3 Yeast
    • 3.3.3.4 Other Sources
  • 3.3.4 Plasmid DNA
    • 3.3.4.1 GigaPrep
    • 3.3.4.2 MaxiPrep
    • 3.3.4.3 MegaPrep
    • 3.3.4.4 MidiPrep
    • 3.3.4.5 MiniPrep
  • 3.3.5 Viral DNA
• 3.4 RNA
  • 3.4.1 Genomic RNA
    • 3.4.1.1 Blood
    • 3.4.1.2 Body Fluids
    • 3.4.1.3 Cell/Cultured Cell
    • 3.4.1.4 FFPE
    • 3.4.1.5 Plant
    • 3.4.1.6 Saliva/Swab
    • 3.4.1.7 Serum/Plasma
    • 3.4.1.8 Tissue
    • 3.4.1.9 Urine
    • 3.4.1.10 Others
  • 3.4.2 Microbial RNA
    • 3.4.2.1 Bacteria
    • 3.4.2.2 Yeast
    • 3.4.2.3 Fungus
    • 3.4.2.4 Others
  • 3.4.3 Viral RNA
  • 3.4.4 Cell-Free RNA
    • 3.4.4.1 Serum/Plasma
    • 3.4.4.2 Others

4 Technology

• 4.1 Technology Summary
• 4.2 Growth-Share Matrix
• 4.3 Silica-Based Technology
• 4.4 Magnetic Particle Technology
• 4.5 Other Technologies

5 Downstream Application

• 5.1 Downstream Applications Summary
• 5.2 Growth-Share Matrix
• 5.3 PCR
• 5.4 qPCR
• 5.5 NGS
• 5.6 Cloning
• 5.7 Microarray
• 5.8 Blotting Techniques
• 5.9 Other Applications

6 End User

• 6.1 End User Summary
• 6.2 Growth-Share Matrix
• 6.3 Academic Research Institutes and Laboratories
• 6.4 Pharmaceutical and Biotechnology Companies
• 6.5 Contract Research Organizations
• 6.6 Applied Testing
• 6.7 Clinical Diagnostic Centers

7 Region

• 7.1 Regional Summary
• 7.2 North America
  • 7.2.1 Regional Overview
  • 7.2.2 Driving Factors for Market Growth
  • 7.2.3 Factors Challenging the Market
  • 7.2.4 By Country
    • 7.2.4.1 U.S.
    • 7.2.4.2 Canada
• 7.3 Europe
  • 7.3.1 Regional Overview
  • 7.3.2 Driving Factors for Market Growth
  • 7.3.3 Factors Challenging the Market
  • 7.3.4 By Country
    • 7.3.4.1 Germany
    • 7.3.4.2 U.K.
    • 7.3.4.3 France
    • 7.3.4.4 Italy
    • 7.3.4.5 Spain
    • 7.3.4.6 Netherlands
    • 7.3.4.7 Poland
    • 7.3.4.8 Portugal
    • 7.3.4.9 Russia
    • 7.3.4.10 Rest-of-Europe
• 7.4 Asia Pacific
  • 7.4.1 Regional Overview
  • 7.4.2 Driving Factors for Market Growth
  • 7.4.3 Factors Challenging the Market
  • 7.4.4 By Country
    • 7.4.4.1 Australia
    • 7.4.4.2 China
    • 7.4.4.3 India
    • 7.4.4.4 Japan
    • 7.4.4.5 Malaysia
    • 7.4.4.6 South Korea
    • 7.4.4.7 Thailand
    • 7.4.4.8 Taiwan
    • 7.4.4.9 Singapore
    • 7.4.4.10 Indonesia
    • 7.4.4.11 Philippines
    • 7.4.4.12 Rest-of-Asia-Pacific
• 7.5 Latin America
  • 7.5.1 Regional Overview
  • 7.5.2 Driving Factors for Market Growth
  • 7.5.3 Factors Challenging the Market
  • 7.5.4 By Country
    • 7.5.4.1 Argentina
    • 7.5.4.2 Brazil
    • 7.5.4.3 Chile
    • 7.5.4.4 Mexico
    • 7.5.4.5 Colombia
    • 7.5.4.6 Rest-of-Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Regional Overview
  • 7.6.2 Driving Factors for Market Growth
  • 7.6.3 Factors Challenging the Market
  • 7.6.4 By Country
    • 7.6.4.1 Saudi Arabia
    • 7.6.4.2 South Africa
    • 7.6.4.3 U.A.E.
    • 7.6.4.4 Rest-of-Middle East and Africa

8 Markets - Competitive Benchmarking & Company Profiles

• 8.1 Product Benchmarking
  • 8.1.1 Product Benchmarking (by Source Type)
    • 8.1.1.1 DNA
    • 8.1.1.2 RNA
• 8.2 Key Strategies and Developments (by Company)
  • 8.2.1 Partnerships, Collaborations, and Business Expansions
  • 8.2.2 New Offerings
• 8.3 Company Share Analysis
  • 8.3.1 DNA
    • 8.3.1.1 Cell-Free DNA
    • 8.3.1.2 Genomic DNA
    • 8.3.1.3 Microbial DNA
    • 8.3.1.4 Plasmid DNA
    • 8.3.1.5 Viral DNA
  • 8.3.2 RNA
    • 8.3.2.1 Cell-Free RNA
    • 8.3.2.2 Genomic RNA
    • 8.3.2.3 Microbial RNA
    • 8.3.2.4 Viral RNA
• 8.4 Company Profiles
  • 8.4.1 Agilent Technologies, Inc.
    • 8.4.1.1 Overview
    • 8.4.1.2 Top Products/Product Portfolio
    • 8.4.1.3 Top Competitors
    • 8.4.1.4 Target Customers
    • 8.4.1.5 Key Personnel
    • 8.4.1.6 Analyst View
  • 8.4.2 AutoGen Inc.
    • 8.4.2.1 Overview
    • 8.4.2.2 Top Products/Product Portfolio
    • 8.4.2.3 Top Competitors
    • 8.4.2.4 Target Customers
    • 8.4.2.5 Key Personnel
    • 8.4.2.6 Analyst View
  • 8.4.3 Bio-Rad Laboratories, Inc.
    • 8.4.3.1 Overview
    • 8.4.3.2 Top Products/Product Portfolio
    • 8.4.3.3 Top Competitors
    • 8.4.3.4 Target Customers
    • 8.4.3.5 Key Personnel
    • 8.4.3.6 Analyst View
  • 8.4.4 F. Hoffmann-La Roche AG
    • 8.4.4.1 Overview
    • 8.4.4.2 Top Products/Product Portfolio
    • 8.4.4.3 Top Competitors
    • 8.4.4.4 Target Customers
    • 8.4.4.5 Key Personnel
    • 8.4.4.6 Analyst View
  • 8.4.5 Merck KGaA
    • 8.4.5.1 Overview
    • 8.4.5.2 Top Products/Product Portfolio
    • 8.4.5.3 Top Competitors
    • 8.4.5.4 Target Customers
    • 8.4.5.5 Key Personnel
    • 8.4.5.6 Analyst View
  • 8.4.6 Macherey-Nagel GmbH & Co KG
    • 8.4.6.1 Overview
    • 8.4.6.2 Top Products/Product Portfolio
    • 8.4.6.3 Top Competitors
    • 8.4.6.4 Target Customers
    • 8.4.6.5 Key Personnel
    • 8.4.6.6 Analyst View
  • 8.4.7 New England Biolabs
    • 8.4.7.1 Overview
    • 8.4.7.2 Top Products/Product Portfolio
    • 8.4.7.3 Top Competitors
    • 8.4.7.4 Target Customers
    • 8.4.7.5 Key Personnel
    • 8.4.7.6 Analyst View
  • 8.4.8 Omega Bio-tek, Inc.
    • 8.4.8.1 Overview
    • 8.4.8.2 Top Products/Product Portfolio
    • 8.4.8.3 Top Competitors
    • 8.4.8.4 Target Customers
    • 8.4.8.5 Key Personnel
    • 8.4.8.6 Analyst View
  • 8.4.9 QIAGEN N.V.
    • 8.4.9.1 Overview
    • 8.4.9.2 Top Products/Product Portfolio
    • 8.4.9.3 Top Competitors
    • 8.4.9.4 Target Customers
    • 8.4.9.5 Key Personnel
    • 8.4.9.6 Analyst View
  • 8.4.10 Revvity, Inc. (PerkinElmer, Inc.)
    • 8.4.10.1 Overview
    • 8.4.10.2 Top Products/Product Portfolio
    • 8.4.10.3 Top Competitors
    • 8.4.10.4 Target Customers
    • 8.4.10.5 Key Personnel
    • 8.4.10.6 Analyst View
  • 8.4.11 Thermo Fisher Scientific Inc.
    • 8.4.11.1 Overview
    • 8.4.11.2 Top Products/Product Portfolio
    • 8.4.11.3 Top Competitors
    • 8.4.11.4 Target Customers
    • 8.4.11.5 Key Personnel
    • 8.4.11.6 Analyst View
  • 8.4.12 Promega Corporation
    • 8.4.12.1 Overview
    • 8.4.12.2 Top Products/Product Portfolio
    • 8.4.12.3 Top Competitors
    • 8.4.12.4 Target Customers
    • 8.4.12.5 Key Personnel
    • 8.4.12.6 Analyst View
  • 8.4.13 Zymo Research
    • 8.4.13.1 Overview
    • 8.4.13.2 Top Products/Product Portfolio
    • 8.4.13.3 Top Competitors
    • 8.4.13.4 Target Customers
    • 8.4.13.5 Key Personnel
    • 8.4.13.6 Analyst View
  • 8.4.14 LGC Biosearch Technologies
    • 8.4.14.1 Overview
    • 8.4.14.2 Top Products/Product Portfolio
    • 8.4.14.3 Top Competitors
    • 8.4.14.4 Target Customers
    • 8.4.14.5 Key Personnel
    • 8.4.14.6 Analyst View
  • 8.4.15 Danaher Corporation
    • 8.4.15.1 Overview
    • 8.4.15.2 Top Products/Product Portfolio
    • 8.4.15.3 Top Competitors
    • 8.4.15.4 Target Customers
    • 8.4.15.5 Key Personnel
    • 8.4.15.6 Analyst View

9 Research Methodology

• 9.1 Data Sources
  • 9.1.1 Primary Data Sources
  • 9.1.2 Secondary Data Sources
  • 9.1.3 Data Triangulation
• 9.2 Market Estimation and Forecast